Risk Assessment Report on 1,3,4,6,7,8-HEXAHYDRO-4,6,6,7,8,8-HEXAMETHYLCYCLOPENTA-γ-2-BENZOPYRAN (HHCB)
Human Health Part (indirect exposure)

CAS No: 1222-05-5
EINECS No: 214-946-9

The SCHER adopted this opinion at its 23rd plenary on 6 May 2008
About the Scientific Committees

Three independent non-food Scientific Committees provide the Commission with the scientific advice it needs when preparing policy and proposals relating to consumer safety, public health and the environment. The Committees also draw the Commission's attention to the new or emerging problems which may pose an actual or potential threat.

They are: the Scientific Committee on Consumer Products (SCCP), the Scientific Committee on Health and Environmental Risks (SCHER) and the Scientific Committee on Emerging and Newly-Identified Health Risks (SCENIHR) and are made up of external experts.

In addition, the Commission relies upon the work of the European Food Safety Authority (EFSA), the European Medicines Evaluation Agency (EMEA), the European Centre for Disease prevention and Control (ECDC) and the European Chemicals Agency (ECHA).

SCHER

Questions relating to examinations of the toxicity and ecotoxicity of chemicals, biochemicals and biological compound whose use may have harmful consequences for human health and the environment.

In particular, the Committee addresses questions related to new and existing chemicals, the restriction and marketing of dangerous substances, biocides, waste, environmental contaminants, plastic and other materials used for water pipe work (e.g. new organics substances), drinking water, indoor and ambient air quality. It addresses questions relating to human exposure to mixtures of chemicals, sensitisation and identification of endocrine disrupters.

Scientific Committee members
Herman Autrup, Peter Calow, Wolfgang Dekant, Helmut Greim, Wojciech Hanke, Colin Janssen, Bo Jansson, Hannu Komulainen, Ole Ladefoged, Jan Linders, Inge Mangelsdorf, Marco Nuti, Anne Steenhout, Jose Tarazona, Emanuela Testai, Marco Vighi, Matti Viluksela

Contact:
European Commission
Health & Consumer Protection DG
Directorate C: Public Health and Risk Assessment
Unit C7 - Risk Assessment
Office: B232 B-1049 Brussels
Sanco-Sc8-Secretariat@ec.europa.eu

© European Commission 2008

The opinions of the Scientific Committees present the views of the independent scientists who are members of the committees. They do not necessarily reflect the views of the European Commission. The opinions are published by the European Commission in their original language only.

ACKNOWLEDGMENTS

The rapporteur is acknowledged for her valuable contribution to this opinion:
Prof. W. Dekant Universität Würzburg, Germany

Keywords: SCHER, scientific opinion, risk assessment, Regulation 793/93, 1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylcyclopenta-γ-2-benzopyran (HHCB), human health, CAS 1222-05-5

Opinion to be cited as:
SCHER, scientific opinion on the risk assessment report on 1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylcyclopenta-γ-2-benzopyran (HHCB), CAS 1222-05-5, human health part, 6 May 2008.
# TABLE OF CONTENTS

ACKNOWLEDGMENTS ........................................................................................................ 3
1. BACKGROUND ........................................................................................................ 5
2. TERMS OF REFERENCE ....................................................................................... 5
3. OPINION ............................................................................................................... 5
   3.1 General comments ....................................................................................... 5
   3.2 Specific comments ....................................................................................... 5
      3.2.1 Exposure assessment ......................................................................... 5
      3.2.2 Effect assessment .............................................................................. 5
      3.2.3 Risk characterisation ......................................................................... 5
4. LIST OF ABBREVIATIONS .................................................................................. 6
1. BACKGROUND

Council Regulation 793/93 provides the framework for the evaluation and control of the risk of existing substances. Member States prepare Risk Assessment Reports on priority substances. The Reports are then examined by the Technical Committee under the Regulation and, when appropriate, the Commission invites the Scientific Committee on Health and Environmental Risks (SCHER) to give its opinion.

2. TERMS OF REFERENCE

On the basis of the examination of the Risk Assessment Report the SCHER is invited to examine the following issues:

(1) Does the SCHER agree with the conclusions of the Risk Assessment Report?
(2) If the SCHER disagrees with such conclusions, it is invited to elaborate on the reasons.
(3) If the SCHER disagrees with the approaches or methods used to assess the risks, it is invited to suggest possible alternatives.

3. OPINION

3.1 General comments

SCHER had previously commented on the Risk Assessment Report for 1,3,4,6,7,8-Hexahydro-4,6,6,7,8-hexamethylcyclopenta-γ-2-benzopyran (HHCB). SCHER agreed with the conclusions regarding hazard assessment and risk assessment made. However, in the previous RAR, risk assessment for humans exposed via the environment was not performed since the RAR covering the environmental aspects of HHCB was not completed. This opinion now addresses the risk assessment for indirect exposures via the environment.

3.2 Specific comments

3.2.1 Exposure assessment

The RAR considers exposure with food, drinking water and human milk as potential relevant pathways. SCHER agrees with this assessment and also agrees that inhalation is not a relevant exposure pathway due to very low concentrations of HHCB in ambient air. Food and water exposure assessment is performed by using EUSES and total daily intake of HHCB is estimated as 2.6 µg/kg bw per day for the local scenario and 0.097 µg/kg bw per day for the regional scenario. Exposure assessment for infants regarding uptake with mothers milk has been addressed in the RAR in July of 2006.

3.2.2 Effect assessment

No new information besides that already reviewed by SCHER was available.

3.2.3 Risk characterisation

The risk characterization performed in the RAR uses the MOS approach and is performed for oral exposures with food and water for adults and for breast-fed babies. For adults, the MOS regarding combined exposures and repeated dose toxicity are very high and SCHER therefore agrees with conclusion ii)\(^1\). Conclusion ii) is also supported regarding

\(^1\) According to the Technical Guidance Document on Risk Assessment – European Communities 2003:
- conclusion i): There is a need for further information and/or testing;
- conclusion ii): There is at present no need for further information and/or testing and for risk reduction measures beyond those which are being applied already;
- conclusion iii): There is a need for limiting the risks; risk reduction measures which are already being applied shall be taken into account
mutagenicity and carcinogenicity since HHCB is non-genotoxic. An additional reference to 4.1.3.4.2, reproductive toxicity, may help to clarify which toxicity studies were used as basis to derive an MOS of 106 based on the maximal combined exposure of app. 0.1 mg/kg bw/day and to give a better justification for the selected minimal MOS of 50. However, SCHER agrees with conclusion ii) for reproductive and developmental effects since a conservative assessment of hazard and exposures gives a MOS slightly above 100. SCHER suggests including a table with an overview of estimated exposures, NOAELs for the toxicity endpoints relevant to the risk assessment, and derived MOS-values.

4. LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUSES</td>
<td>European Union System for the Evaluation of Substances</td>
</tr>
<tr>
<td>MOS</td>
<td>Margin of Safety</td>
</tr>
<tr>
<td>NOAEL</td>
<td>No Observed Adverse Effect Level</td>
</tr>
<tr>
<td>RAR</td>
<td>Risk Assessment Report</td>
</tr>
</tbody>
</table>